生物技术公司Calidi Biotherapeutics（简称Calidi）近日宣布与人工智能企业Transferai建立战略合作伙伴关系。双方将重点运用智能代理人工智能技术，显著提升抗癌候选药物Cld-401的新药临床试验申请准备工作的效率。
通过此次合作，Calidi计划借助Transferai先进的AI解决方案优化IND申报流程中的关键环节。智能代理AI系统将协助研究人员更高效地整合临床前研究数据，加速申报材料的生成与审核，从而缩短药物开发周期。
Cld-401作为Calidi公司核心的肿瘤治疗候选药物，此次与AI技术企业的合作标志着其商业化进程进入新阶段。该战略合作不仅展现了生物科技与人工智能的深度融合趋势，更为创新药物研发提供了数字化转型的新范式。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.